Beligas HCG 10000

AOD9604 is a modified version of the hGH fragment 176-191 peptide (contains a di-sulfide bridge) and thus a derivative of human growth hormone (hGH). Originally developed as a lipolytic (fat burning) compound, AOD9604 has shown benefit in studies of heart disease, osteoarthritis/cartilage repair, and metabolic syndrome. AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis in animal studies.

BPC-157 is a penta-decapeptide composed of 15 amino acids. It is a partial sequence of the body protection compound (BPC) that was discovered in and isolated from human gastric juice. Animal studies have shown it to accelerate the healing of many different wounds, including muscle, tendon and damaged ligaments. Additionally, BPC 157 has shown to protect organs and aids in the prevention of gastric ulcers. BPC-157 acts systemically in the digestive tract to combat leaky gut, IBS, gastro-intestinal cramps, and Crohn’s disease. This peptide has been known to exhibit analgesic characteristics. Research has shown its ability to help skin burns heal at a faster rate by increasing blood flow to damaged tissues. BPC-157 significantly accelerates reticulin and collagen formation as well as angiogenesis together with stimulation of macrophages and fibroblasts infiltration representing a potential therapeutic tool in wound healing management.

Retatrutide is a Triple–Hormone-Receptor Agonist. Retatrutide is an investigational single molecule that activates the body’s receptors for three hormones – glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), and is being studied for the treatment of obesity. Retatrutide is an acylated peptide suitable for weekly injection.